Relmada Therapeutics Inc (RLMD)
3.00
-0.04
(-1.32%)
USD |
NASDAQ |
May 31, 16:00
3.01
+0.01
(+0.33%)
Pre-Market: 20:00
Relmada Therapeutics Free Cash Flow (Quarterly): -13.04M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -13.04M |
December 31, 2023 | -10.25M |
September 30, 2023 | -11.63M |
June 30, 2023 | -13.27M |
March 31, 2023 | -16.51M |
December 31, 2022 | -35.88M |
September 30, 2022 | -26.86M |
June 30, 2022 | -21.63M |
March 31, 2022 | -19.43M |
December 31, 2021 | -37.66M |
September 30, 2021 | -20.92M |
June 30, 2021 | -17.21M |
March 31, 2021 | -16.09M |
December 31, 2020 | -6.929M |
September 30, 2020 | -12.50M |
June 30, 2020 | -4.954M |
March 31, 2020 | -3.425M |
September 30, 2019 | -2.534M |
June 30, 2019 | -3.667M |
March 31, 2019 | -2.012M |
December 31, 2018 | -3.148M |
September 30, 2018 | -1.671M |
Date | Value |
---|---|
June 30, 2018 | -2.276M |
March 31, 2018 | -1.625M |
December 31, 2017 | -1.132M |
September 30, 2017 | -0.9816M |
June 30, 2017 | -1.018M |
March 31, 2017 | -1.875M |
December 31, 2016 | -1.453M |
September 30, 2016 | -2.169M |
June 30, 2016 | -2.849M |
March 31, 2016 | -3.690M |
December 31, 2015 | -3.950M |
September 30, 2015 | -3.217M |
June 30, 2015 | -4.493M |
March 31, 2015 | -4.435M |
December 31, 2014 | -4.99M |
September 30, 2014 | -2.333M |
February 28, 2014 | -0.0035M |
November 30, 2013 | -0.0091M |
August 31, 2013 | -0.0054M |
May 31, 2013 | -0.0068M |
February 28, 2013 | -0.0029M |
November 30, 2012 | 0.0015M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-37.66M
Minimum
Dec 2021
-2.534M
Maximum
Sep 2019
-15.49M
Average
-13.27M
Median
Jun 2023
Free Cash Flow (Quarterly) Benchmarks
Cyclacel Pharmaceuticals Inc | -0.483M |
Lifecore Biomedical Inc | -- |
Harrow Inc | -4.738M |
Corvus Pharmaceuticals Inc | -5.157M |
Aquestive Therapeutics Inc | -10.41M |